Copanlisib
| CAS No. | 1032568-63-0 |
|---|---|
| MDL No. | MFCD18633201 |
| MF | C23H28N8O4 |
| MW | 480.50 |
| InChI Key | MWYDSXOGIBMAET-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Copanlisib is an imidazoquinazoline derivative substituted with a (2-aminopyrimidine-5-carbonyl)amino group at position 5, a methoxy group at position 7, and a 3-(morpholin-4-yl)propoxy group at position 8. It is an intravenous pan-class I phosphatidylinositol 3-kinase (EC 2.7.1.137) inhibitor used to treat relapsed follicular lymphoma in patients who have received at least two prior systemic therapies. It functions as an antineoplastic agent and apoptosis inducer, and belongs to the classes of morpholines, aromatic ethers, diethers, tertiary amino compounds, secondary carboxamides, pyrimidinecarboxamides, aminopyrimidines, and imidazoquinazolines.
| CAS No. | 1032568-63-0 |
|---|---|
| Product Name | Copanlisib |
Biological Targets
PIK3CA·PIK3CD
Associated Conditions
prostate cancer·lymphoma·diffuse large B-cell lymphoma·breast cancer·neoplasm·
* The information provided here is compiled from public sources and is for reference only.
